Melaena on apixaban with renal impairment
Mr A is a 74-year-old retired teacher with permanent atrial fibrillation. He takes apixaban 5 mg twice daily; his renal function has drifted and his latest eGFR is 31 mL/min/1.73 m², with creatinine 156 µmol/L, weight 78 kg and no other dose-reduction criteria. He has no history of previous bleeding and takes no aspirin or NSAID. He is brought to the emergency department after a syncopal episode at home and 36 hours of black, tarry stools. He is pale and clammy: BP 102/64 mmHg, pulse 112 beats/min, respiratory rate 22, SpO2 97% on air, temperature 36.4°C. Bloods show haemoglobin 74 g/L, platelets 210 × 10⁹/L, urea 18 mmol/L, creatinine 156 µmol/L. His last apixaban dose was 10 hours ago. The on-call gastroenterologist is in theatre and the endoscopy list is full until tomorrow morning. The patient asks whether he can just have a blood transfusion and go home.
1. Outline your immediate resuscitation and transfusion plan, including target haemoglobin and why.
Read the worked answer
Immediate priorities. This is a major upper GI bleed with haemodynamic compromise (shock index >1) and a high Glasgow-Blatchford score. He is not for discharge.
- Airway/breathing/circulation: high-flow oxygen if needed, two large-bore cannulae, group and save plus crossmatch 4 units, hourly observations, urinary catheter, strict fluid balance.
- Resuscitate with crystalloid cautiously (250–500 mL boluses) to a systolic BP of about 90–100 mmHg; over-filling can raise portal pressure and worsen bleeding.
- Transfuse restrictively: a threshold of 70 g/L, or 80 g/L if there is cardiovascular disease. He has AF but no ischaemic heart disease; target 70–90 g/L, not a 'normal' haemoglobin. Over-transfusion increases rebleeding and thrombosis.
- Start a proton pump inhibitor (e.g. omeprazole 80 mg IV then infusion) and consider a prokinetic before endoscopy. Do not give terlipressin unless variceal bleeding is suspected.
- Correct any coagulopathy only if bleeding is ongoing; do not routinely give FFP or platelets.
He needs senior medical and gastroenterology review now, not tomorrow's routine list. A restrictive strategy is safe and evidence-based; the decision that matters is recognising shock and not being reassured by a single haemoglobin value.
2. How would you manage his apixaban and plan endoscopy? Address reversal agents and their limitations.
Read the worked answer
Apixaban. Stop apixaban. The last dose was 10 hours ago and renal impairment prolongs its effect. For life-threatening bleeding, specific reversal is considered: andexanet alfa (restricted access) or four-factor prothrombin complex concentrate 25–50 units/kg. These are not routine for a stable patient and carry thrombotic risk; discuss with haematology. Do not give fresh frozen plasma or vitamin K - neither reverses a factor Xa inhibitor.
Endoscopy. Resuscitate first, then endoscopy within 24 hours; if he rebleeds or remains unstable, it becomes an emergency. Do not delay endoscopy to wait for reversal. The endoscopist should be told about the DOAC and renal function so they can plan dual therapy if a bleeding ulcer is found.
Reasoning. Reversal is for major bleeding, not for an abnormal coagulase test. The common error is to give PCC automatically and then delay endoscopy. The safer sequence is resuscitation, hold the anticoagulant, urgent endoscopy, and targeted reversal only if bleeding cannot be controlled. Document the discussion with haematology and the patient.
3. Two days later he is stable. Discuss restarting anticoagulation and what you would say to him about stroke and bleeding risk.
Read the worked answer
Restarting. Once haemostasis is confirmed and he is stable, restart apixaban. His stroke risk is not zero: age 74 alone scores 1 on CHA2DS2-VASc, and hypertension or diabetes would add more. His bleeding risk is also high. The decision is a balance, not a reflex.
Timing. Usually restart 24–72 hours after endoscopic haemostasis, guided by the endoscopist and the severity of bleeding. Restarting earlier increases rebleeding; delaying too long increases stroke risk. Do not stop permanently because of one bleed unless the bleed was uncontrollable and the stroke risk is low.
Dose. His creatinine is 156 µmol/L but he has only one dose-reduction criterion (creatinine ≥133 µmol/L); age and weight do not qualify. Apixaban 5 mg twice daily remains appropriate, with renal review.
Communication. Explain that the bleeding was probably from an ulcer, that his blood thinner made it worse, and that stopping it would raise his stroke risk. Use absolute numbers rather than vague warnings. Agree a plan: apixaban with a PPI, avoid NSAIDs and aspirin, and review renal function. Give written advice and a direct contact if he has black stools or dizziness. Document his preferences and the shared decision.